Carl Dambkowski Sells 12,583 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Director Carl Dambkowski sold 12,583 shares of Oruka Therapeutics stock in a transaction on Friday, June 12th. The shares were sold at an average price of $70.11, for a total transaction of $882,194.13. Following the completion of the sale, the director owned 38,743 shares in the company, valued at approximately $2,716,271.73. This trade represents a 24.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Carl Dambkowski also recently made the following trade(s):

• On Thursday, June 11th, Carl Dambkowski sold 22,417 shares of Oruka Therapeutics stock. The shares were sold at an average price of $70.13, for a total transaction of $1,572,104.21.
• On Thursday, May 21st, Carl Dambkowski sold 105,000 shares of Oruka Therapeutics stock. The shares were sold at an average price of $58.97, for a total transaction of $6,191,850.00.

Oruka Therapeutics Stock Up 2.1%

NASDAQ:ORKA opened at $69.89 on Friday. The stock has a market cap of $4.22 billion, a P/E ratio of -36.03 and a beta of -0.26. The firm’s fifty day simple moving average is $63.40 and its 200 day simple moving average is $43.94. Oruka Therapeutics, Inc. has a twelve month low of $10.77 and a twelve month high of $91.00.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.04. On average, analysts expect that Oruka Therapeutics, Inc. will post -2.06 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on ORKA shares. UBS Group boosted their target price on shares of Oruka Therapeutics from $75.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. Guggenheim set a $200.00 target price on shares of Oruka Therapeutics and gave the company a “buy” rating in a report on Monday, April 27th. Wedbush set a $165.00 target price on shares of Oruka Therapeutics in a report on Monday, April 27th. BTIG Research restated a “buy” rating and set a $151.00 target price on shares of Oruka Therapeutics in a report on Thursday, May 14th. Finally, Barclays boosted their target price on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the company an “overweight” rating in a report on Monday, April 27th. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $131.30.

Hedge Funds Weigh In On Oruka Therapeutics

A number of hedge funds have recently bought and sold shares of ORKA. Fairmount Funds Management LLC increased its stake in Oruka Therapeutics by 9.9% during the 3rd quarter. Fairmount Funds Management LLC now owns 3,705,262 shares of the company’s stock valued at $71,252,000 after purchasing an additional 333,340 shares in the last quarter. Secure Asset Management LLC bought a new stake in Oruka Therapeutics during the 4th quarter valued at about $2,475,000. Avoro Capital Advisors LLC bought a new stake in Oruka Therapeutics during the 3rd quarter valued at about $25,640,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new stake in Oruka Therapeutics during the 3rd quarter valued at about $296,000. Finally, Commodore Capital LP increased its stake in Oruka Therapeutics by 23.5% during the 3rd quarter. Commodore Capital LP now owns 1,753,054 shares of the company’s stock valued at $33,711,000 after purchasing an additional 333,340 shares in the last quarter. Institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of novel peptide?based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell?permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.